Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-925 in Sleep-Deprived Healthy Adults
NCT03522506Phase 1Completed
- Sponsor
- Takeda
- Start
- May 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of danavorexton in narcolepsy (4 arms), sponsored by Takeda. Primary endpoint: Latency to Sleep Onset on Maintenance of Wakefulness Test. Started May 2018; status: completed.
02
Drugs
danavorexton
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT03522506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03522506.